NeuroSense Therapeutics Files 6-K with Proxy Statement
Ticker: NRSNW · Form: 6-K · Filed: Nov 21, 2025 · CIK: 1875091
Sentiment: neutral
Topics: disclosure, corporate-governance, proxy-statement
TL;DR
NeuroSense filed a 6-K with a proxy statement for a special meeting - watch for shareholder votes.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on November 21, 2025, to report information for the month of November 2025. The filing includes Exhibit 99.1, which is a Notice and Proxy Statement for a Special Meeting.
Why It Matters
This filing indicates upcoming corporate actions or shareholder votes that could impact the company's strategic direction or governance.
Risk Assessment
Risk Level: low — A 6-K filing is typically for routine disclosures and does not inherently signal significant financial or operational risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- November 21, 2025 (date) — Filing date
- Exhibit 99.1 (document) — Included exhibit
FAQ
What is the purpose of the Notice and Proxy Statement included in the filing?
The Notice and Proxy Statement (Exhibit 99.1) is for a Special Meeting, indicating that shareholder votes or decisions are required on specific matters.
What is the filing date of this Form 6-K?
This Form 6-K was filed on November 21, 2025.
What is the primary business of NeuroSense Therapeutics Ltd. according to the filing?
The filing lists NeuroSense Therapeutics Ltd. under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Does NeuroSense Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel, with its principal executive offices located at 11 HaMenofim Street, Building B.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2025-11-21 06:36:37
Filing Documents
- ea0266625-6k_neuro.htm (6-K) — 28KB
- ea026662501ex99-1_neuro.htm (EX-99.1) — 78KB
- ea026662501ex99-2_neuro.htm (EX-99.2) — 10KB
- tneurosense_logo.jpg (GRAPHIC) — 118KB
- tneurosense_logo1.jpg (GRAPHIC) — 118KB
- tproxy_001.jpg (GRAPHIC) — 1237KB
- tproxy_002.jpg (GRAPHIC) — 1062KB
- 0001213900-25-113300.txt ( ) — 3608KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ FORM 6-K _______________ Report of Foreign Private Issuer Pursuant to Rule 13a -16 or 15d -16 Under the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001 -41084 _______________ NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English) _______________ NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972 -9 - 7996183 (Address of principal executive offices) _______________ Indicate by check mark whether the registrant files or will file annual reports under cover Form 20 -F or Form 40 -F . Form 20 -F             Form 40 -F   INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Attached hereto and incorporated herein by reference are the following exhibits: Exhibit 99.1   Notice and Proxy Statement for the Special Meeting of Shareholders of the registrant scheduled for December 30, 2025 Exhibit 99.2   Proxy Card This Report on Form 6 -K is hereby incorporated by reference into registrant’s Registration Statements on Form S -8 (File No. 333 -262480 and 333 -289658 ) and Form F -3 (File No. 333 -269306 , 333 -260338 , 333 -283656 , 333 -284051 and 333 -291122 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   NeuroSense Therapeutics Ltd. Dated: November 21, 2025   By:   /s/ Alon Ben-Noon         Alon Ben -Noon         Chief Executive Officer 2